U.S. Pharma Stock News

Akamai Technologies (AKAM) just rolled out its ISV Catalyst partner program and a separate strategic tie up with Visa, moves that quietly tighten its grip on AI ready cloud infrastructure and secure, agent driven commerce. See our latest analysis for Akamai Technologies. These moves land as Akamai’s 90 day share price return of 17.83 percent contrasts with a negative year to date share price return of 6.92 percent and a one year total shareholder return of 8.35 percent in the red, suggesting...

If you are wondering whether AbbVie is still attractive after its massive run, or if the value story has already played out, this breakdown outlines the key factors that can help you assess whether the current price makes sense. The stock has climbed 28.1% year to date and 32.2% over the last year, with a 58.2% return over three years and 165.4% over five. This performance naturally raises questions about how much upside may remain from here. Recent headlines have focused on AbbVie's...

Wondering if BeOne Medicines is still a smart buy after its big run up, or if the easy money has already been made? Here is a closer look at what the current share price implies about its long term potential. The stock has been volatile lately, slipping 6.3% over the last month but still up 1.9% in the past week, and 69.4% year to date and 71.6% over the past year. This suggests the market is rapidly updating its view of the company. Recent headlines around BeOne Medicines have centered on...

If you are wondering whether Starbucks at around $84 a share is a bargain or a value trap right now, you are not alone. This makes it a good moment to unpack what the market is really pricing in. Over the past year the stock is down about 3.4%, with a softer 8.2% slide year to date, but a modest 1.5% gain over the last month hints that sentiment might be stabilizing as investors reassess its long term growth story. Recently, markets have been weighing Starbucks strategic push into new store...

Alibaba Group Holding (NYSE:BABA) is back in the spotlight after a flurry of AI focused moves, from massive accelerator orders with global chipmakers to new multilingual models and agent platforms rolling out across its ecosystem. See our latest analysis for Alibaba Group Holding. All of this AI momentum is landing against a backdrop where Alibaba’s share price has pulled back, with a 1 month share price return of negative 6.6% and a 3 month share price return of negative 14.5%. At the same...

ASA Gold and Precious Metals (ASA) has just been spotlighted as a rare opportunity in the metals and mining space, after its strong earnings and revenue growth stood out during the latest US market rally. See our latest analysis for ASA Gold and Precious Metals. That attention has come on the back of powerful price action, with a roughly 27 percent 30 day share price return and a 192 percent year to date share price return. The 1 year total shareholder return above 200 percent signals that...

Alexandria Real Estate Equities (ARE) is back in the spotlight as multiple class action lawsuits, a sharp guidance reset, and an S&P outlook cut converge, forcing investors to reassess this beaten down life science REIT. See our latest analysis for Alexandria Real Estate Equities. All of this legal and ratings pressure has played out in the numbers, with Alexandria’s share price now at $48.76 after a roughly 50 percent year to date share price decline and an even steeper multi year total...

Wondering if Sea at around $126 a share is still a smart buy or if the big gains are already behind it? This breakdown will help you decide whether the current price matches the company’s long term potential. The stock is up 6.1% over the last week and 20.4% year to date, even after a choppier patch that left it down 7.4% over the last month and still 35.8% lower over 5 years. Recent headlines have focused on Sea sharpening its focus on profitability and capital discipline, including pulling...

In December 2025, Repligen Corporation launched three new high-performance chromatography resins, AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA, built on Tantti™ DuloCore™ technology to support advanced bioprocessing and gene therapy applications. By extending its proteins and viral-vector-focused resin portfolio ahead of broader chromatography launches expected in 2026, Repligen is positioning itself as a more integral tools provider for next-generation gene therapy...

Earlier this week, Home Depot reaffirmed its fiscal 2025 guidance and issued a cautious 2026 outlook, pointing to ongoing housing market softness, restrained discretionary project spending, and a modest sales and earnings growth profile while it prioritizes Pro customer relationships and integrates recent acquisitions. The update also flagged a recent security issue involving leaked internal credentials, adding an operational risk angle to an already macro-sensitive business story built...

Netskope (NTSK) just cleared its first post IPO hurdle with earnings that beat expectations, and the market is now trying to square that growth story with widening losses. See our latest analysis for Netskope. Even with that upbeat debut, the 90 day share price return of negative 18.5 percent and year to date share price return of negative 17.7 percent show momentum has cooled lately. This suggests investors are still recalibrating growth potential against heavier reported losses. If Netskope...

Pinterest (PINS) has quietly outperformed the market over the past month, climbing about 5%, even as the stock remains well below its highs after a rough past 3 months. See our latest analysis for Pinterest. That rebound sits against a tougher backdrop, with the share price still down sharply on a 90 day basis while the three year total shareholder return remains positive. This suggests longer term believers are not capitulating and momentum may be stabilizing rather than accelerating. If...

The U.S. Food and Drug Administration just cleared six on! PLUS nicotine pouch products for Altria Group (NYSE:MO), giving its smoke free portfolio fresh momentum as the company prepares for an orderly CEO and CFO transition. See our latest analysis for Altria Group. At around $58.98, Altria’s recent 30 day share price return of 2.88 percent contrasts with a softer 90 day share price return of negative 9.53 percent. Its five year total shareholder return of 109.89 percent suggests long term...

Earlier in December 2025, Olema Pharmaceuticals, Inc. was added to the S&P Biotechnology Select Industry Index, expanding its presence among publicly traded biotech peers. This index inclusion can be important because it often boosts a company’s visibility with institutional investors and index-tracking funds that may adjust their holdings accordingly. We’ll now examine how Olema’s inclusion in the S&P Biotechnology Select Industry Index shapes its investment narrative and future investor...

Brown-Forman (BF.B) has quietly slipped this year, with shares down about 28% year to date, even as revenue and net income are still growing. That disconnect is where the story gets interesting. See our latest analysis for Brown-Forman. After a tough run that has left the year to date share price return at around negative 28 percent, the stock now trades at about 26 dollars and 89 cents. This suggests sentiment has faded even as fundamentals keep grinding higher. If this kind of reset has you...

UiPath NYSE:PATH is back in focus after being tapped to join the S&P MidCap 400, a step up that can reshape who owns the stock and how it trades heading into 2026. See our latest analysis for UiPath. The index news caps a strong run, with a 1 month share price return of roughly 29 percent and a 3 month share price return above 40 percent. The 3 year total shareholder return of about 42 percent suggests momentum has been rebuilding after earlier volatility. If UiPath’s surge has you rethinking...

Earlier this week, DLocal announced it has completed its transition to a nine-person, majority independent Board of Directors, adding industry veterans Paco Ybarra and Nelson Mattos and establishing new Nominating & Corporate Governance, Compensation, and Product & Technology committees. This shift marks a meaningful upgrade in governance and oversight, bringing deeper expertise in global financial markets, technology, and risk management to support DLocal’s next phase of development. Next,...

In December 2025, Woodward, Inc. proposed amending its Restated Certificate of Incorporation to remove certain supermajority voting requirements and eliminate cumulative voting in director elections, while reporting GAAP earnings per share of $7.19 on US$3.60 billion in revenue and announcing a US$1.80 billion share repurchase plan. Together with new sales growth targets for 2026 focused on automation and aerospace, these governance and capital allocation moves signal a clearer, more...

ARMOUR Residential REIT recently announced past guidance for a January 2026 monthly cash dividend of US$0.24 per common share and disclosed that its external manager will end a voluntary partial fee waiver after February 1, 2026. At the same time, Stonegate Capital Partners initiated coverage highlighting ARMOUR’s strong interest income growth, lower funding costs, high annualized dividend yield, and discount to book value, drawing fresh attention to the mortgage REIT’s income...

Nu Holdings (NYSE:NU) is back in the spotlight after fresh data underscored just how deeply it has penetrated Brazil’s banking market, and how aggressively it is pursuing full banking licenses across multiple countries. See our latest analysis for Nu Holdings. Those licensing moves are helping to support a strong run in the stock, with Nu Holdings’ share price at $16.74 and a powerful year to date share price return of around 57%. Its three year total shareholder return above 300% shows that...

Recent Performance and What Is Moving the Stock New York Times (NYT) has quietly put together a strong run, with the stock up about 11% over the past month and roughly 23% in the past 3 months. See our latest analysis for New York Times. Zooming out, that recent momentum sits on top of a much stronger backdrop, with New York Times delivering a solid year to date share price return and a standout three year total shareholder return, suggesting investors are steadily pricing in durable digital...

In December 2025, FICO announced that Cotality and Ascend Companies joined its FICO Mortgage Direct License Program, enabling participating tri-merge resellers to generate and deliver FICO Scores directly to lenders with more transparent, flexible pricing and improved operational efficiency. This expansion highlights how FICO is embedding itself more deeply into the mortgage infrastructure, potentially reshaping how credit scores are distributed and priced across the lending ecosystem. Next,...

CoreWeave (CRWV) continues to attract attention after another choppy week, with shares down about 2% on the day but still up roughly 22% over the past week, inviting fresh questions around sustainability. See our latest analysis for CoreWeave. That jumpy trading pattern fits a much bigger story, with CoreWeave’s year to date share price return of roughly 97 percent showing strong momentum despite a sharp 90 day share price pullback and today’s close at 78.87 dollars. If you like the growth...

If you are wondering whether Solaris Energy Infrastructure is still worth buying after such a strong run, you are not alone. That is exactly what this breakdown is going to tackle in plain language. The stock has climbed 10.9% over the past week and is up 53.0% year to date, on top of a striking 59.4% gain over the last year and a 424.2% return over three years and 565.1% over five years. This naturally raises questions about how much upside is left versus the risk of a pullback. Those moves...